Mitigate (ACD&P)
Abstract
The Mitigate Advanced Component Development and Prototypes (ACD&P) Project provides the Joint Force the ability to conduct decontamination and medical actions that enable the quick restoration of combat power; maintain/recover essential functions that are free from the effects of Chemical Biological Radiological and Nuclear (CBRN) hazards; and facilitate the return to pre-incident operational capability as soon as possible. Efforts included in this Project are: (1) Autonomous Decontamination System (ADS) (2) Agent-Directed Therapeutics (AD TX) (3) Antiviral Oral Therapeutic (AVO TX) (4) Botulinum Toxin Therapeutic (BOT TX) (5) Consolidated Nerve Agent Treatment System (CNATS) (6) Medical Decontamination Personnel Skin (MED DECON PS) (7) Reactivating Nerve Agent Treatment System (RNATS) (8) Tactical Contamination Mitigation System (TCMS) (9) Biological Warfare Defense Medical Countermeasures Prototype (BIOPROTO) (10) Discovery of Medical countermeasures Against New and Emerging threats (DOMANE) (11) Service Equipment Decontamination System (SEDS) The Autonomous Decontamination System (ADS) is a new start program in FY24 and provides a semi-autonomous supported capability that relies on precision detection capabilities, modernized decontaminants, and robotics to allow a chemical, biological, radiological and nuclear (CBRN) decontamination squad to provide platoon level thorough decontamination on critical mission equipment. In FY25, ADS will complete prototype assessment(s) for robotic/automated technologies that are applicable to contamination mapping and decontamination operations. Additionally, the program will prepare documentation in support of the Milestone A/Technology Maturity and Risk Reduction Phase (Simplified Acquisition Management Plan (SAMP), Life Cycle Sustainment Plan (LCSP), Test and Evaluation Master Plan (TEMP)) and conduct Systems Requirements Review (SRR). The FY25 new start Agent-Directed Therapeutics (AD TX) will go after multiple virus families to develop and deliver Food and Drug Administration (FDA) approved broad-spectrum antiviral therapeutics drugs against highly contagious emerging threats to the warfighter. Initial drug products will be developed targeting viral hemorrhagic diseases of the Arenavirus and Paramyxovirus viral families. Developed agent directed broad spectrum antivirals therapeutics will be employed after suspected or confirmed exposure to known or potential threat agents to include natural occurring outbreaks providing a rapid treatment response to the warfighter. In FY25, funding initiates the Natural History Study (NHS) and procurement of long lead items. The Antiviral Oral Therapeutics (AVO TX) is a new start program in FY24 and will provide the Joint Force the ability to recover from exposure to biological hazards. Efforts include development of Food and Drug Administration (FDA) approved Medical Countermeasure (MCM) to protect the lives and maintain the battle readiness of the warfighter. In FY25, AVO TX funding supports Natural History Study (NHS) and procurement of long lead Items. The Botulinum Toxin Therapeutic (BOT TX) is a new start program in FY24 and will develop and deliver a U.S. Food and Drug Administration (FDA) approved treatment for the warfighter to treat respiratory depression caused by botulinum intoxication. This intravenous injectable treatment will be developed by reformulating an oral drug product already approved by the FDA. FY25 funding will continue Natural History Study (NHS) and initiate Dose Determination. The Consolidated Nerve Agent Treatment System (CNATS) is a new start program in FY24 and will deliver an FDA-approved autoinjector that combines anticholinergics, atropine and scopolamine, and a new improved oxime. The proposed oxime will have efficacy against emerging threats including Fourth Generation Agents (FGAs). Combining nerve agent treatments into fewer autoinjectors will reduce basic load for service members and increase the survivability for the warfighter in the United States European Command (EUCOM) and United States Indo-Pacific Command (INDOPACOM) arenas. In FY25, the program will release a solicitation and select a performer and initiate device development. Medical Decontamination Personnel Skin (MED DECON PS) is a new start in FY25, and will provide a dry/powder personnel decontamination capability to lessen the effects of chemical warfare nerve agents on the skin. MED DECON PS will provide a broad spectrum chemical skin decontamination capability with low logistics footprint (e.g., shelf life and storage conditions) and reduced sustainment costs in comparison to the currently fielded skin decontaminant Reactive Skin Decontamination Lotion (RSDL). In FY25, MED DECON PS will initiate advanced development of the dry powder decontamination technology. The Reactivator Nerve Agent Treatment System (RNATS) is a new start program in FY24 and will provide the services an FDA-approved improved oxime to address emerging chemical threats and fourth generation agents (FGAs). The program will field a vial formulation as an additional capability and increase the survivability for the warfighter in the United States European Command (EUCOM) and United States Indo-Pacific Command (INDOPACOM) arenas. In FY25, the program will develop and validate the API manufacturing procedures, assays to evaluate the API, and assays to evaluate non-clinical samples, and initiate non-clinical studies. The Tactical Contamination Mitigation System (TCMS) will address gaps related to the decontamination of critical equipment and vehicles and reduce the time and logistics associated with decontamination. TCMS will limit the spread and mitigate the effects of Chemical, Biological, and Radiological (CBR) contamination to allow warfighters to continue their mission for an extended period of time in a high threat, CBR contaminated environment. The effort will mitigate risk to personnel by limiting the potential spread of CBR contamination and eliminate the need for subsequent decontamination to mitigate contamination on military equipment. TCMS, when combined with weathering, may reduce Mission Oriented Protective Posture (MOPP) level requirements. In FY25, TCMS will complete iterative prototype testing, Test and Evaluation Master Plan (TEMP), Simplified Acquisition Management Plan (SAMP), and Capability Development Document (CDD) in support of Milestone B. The Biological Warfare Defense Prototype (BIOPROTO) supports early-phase clinical development and supporting non-clinical safety, tolerability and toxicity data for candidate vaccines and therapeutic drugs prior to transition to System Development & Demonstration. This work provides safe and effective medical defense against validated biological threat agents and emerging infectious disease biothreats including bacteria, toxins, and viruses. This work also involves the evaluation of Food and Drug Administration (FDA) approved therapeutics for operational use, as well as generation of novel drug products and formulations, to enhance level of protection and/or operational utility for the warfighter. This effort reduces programmatic risk of failure in the advanced development phase. The Discovery of Medical Countermeasures Against New and Emerging threats (DOMANE) supports prototype development of emerging technology platforms and technologies to identify medical countermeasures (MCMs), MCM targets, and disease origin and toxicity using the combination of Artificial Intelligence/Machine Learning, organs-on-a-chip, high-throughput screening as well as novel imaging platforms. Additionally, MT4 supports early-phase clinical development of prophylaxis treatments and therapeutic drugs through the use of adaptive clinical trials to provide safe and effective medical defense against validated biological threat agents and emerging infectious disease biothreats including bacteria, toxins, and viruses. This effort reduces programmatic risk of failure in the advanced development phase by developing validated prototypes and generating clinical and supporting non-clinical safety, tolerability and toxicity data for candidate prophylaxis treatments and therapeutic drugs prior to transition to System Development & Demonstration. The Service Equipment Decontamination System (SEDS) program consists of two efforts, Joint SEDS and Special Operations Forces (SOF) Critical Equipment Decontamination (CEDS), which will develop a capability for use by the warfighter during decontamination operations that will provide a quantifiable reduction in the number of personnel experiencing adverse health effects by reducing contamination on equipment, individual combat equipment, and sensitive platform interiors (SEDS). This capability is needed to reduce logistical burdens in order to increase tactical agility and sustain a resilient force posture and align with the National Defense Strategy (NDS). SEDS and CEDS will provide contamination mitigation capabilities for critical equipment exposed to chemical and biological contamination and achieve efficacy levels that allow unprotected post-decontamination exposures for long periods with less than negligible severity effects. FY23 is last year of BA4 funding, program is transitioning to Engineering & Manufacturing Development (EMD).
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2025
- Source ID
- MT4_0603884BP_4_0400_PB_2025
Related Documents
- Root: Chemical and Biological Defense Program - Dem/Val
- Child Accomplishment: 1) ADS - Prototype Development
- Child Accomplishment: 2) AD TX
- Child Accomplishment: 3) AVO TX
- Child Accomplishment: 4) BOT TX
- Child Accomplishment: 5) BOT TX
- Child Accomplishment: 6) CNATS
- Child Accomplishment: 7) CNATS
- Child Accomplishment: 8) MED DECON PS
- Child Accomplishment: 9) RNATS
- Child Accomplishment: 10) TCMS
- Child Accomplishment: 11) BIOPROTO
- Child Accomplishment: 12) DOMANE
- Child Accomplishment: 13) SEDS
- Child Cost Item: 75b80d98773794bd54a34b197eafcad4
- Child Cost Item: c9f053e3087d4cae0fb0f85b7ea8be0d
- Child Cost Item: d1102d978b8bf4c2e0634b474be12f07
- Child Cost Item: 73535c6384f1a508dcb2e20f886a02be
- Child Cost Item: 7648760961d275033fbcbf28e18cf895
- Child Cost Item: d2cb2ca5c2eaeba44d26a97aa4616725
- Child Cost Item: 68ef478286ada5025a5ea7498ff9bc48
- Child Cost Item: 473344aea2da90c70ebe986709736400
- Child Cost Item: c4741a888ed9ff3ccc251abeae98d530
- Child Cost Item: 8075d20be155af6d6ac3429820b7141a
- Child Cost Item: 922fd05f7162597353c35e26f146964d
- Child Cost Item: e30d6469eae01b77a24b8d2f83f05d77
- Child Cost Item: 8e4030b722553aa42ad231591d03184f
- Child Cost Item: 56c8372cd0129ad1290fb4df968e9d8c
- Child Cost Item: 104114d35e8b09a36cbea09d32a8caa5
- Child Cost Item: 4ba167c783b85492872f568ac52949db
- Child Cost Item: 379bf7ae119c9cdce69cb9f43ce112b8
- Child Cost Item: 353fea8d5a15818b8bc7246ced9f2068
- Child Cost Item: 469fc2b93b58fd81347f1d53089b451a
- Child Cost Item: a0cc6e983e05e5d66fe4b5b1965b96fe
- Child Cost Item: e6d8fa5d76d468b78d1bb3d8e90acdaf
- Child Cost Item: 65c23c7535dfcbe5e48753be70710bf5
- Child Cost Item: e70eef0babd3c94cd1ef6996f65d4113
- Child Cost Item: 74a6a0e0e682310574ae0a33e6f6dcda
- Child Cost Item: f027ba809586f0a30792778070a30049
- Child Cost Item: bbc672e9ce6506ce3c96e0f0df165134
- Child Cost Item: fab97ce0b9fb76c274f38c38828ef44b
- Child Cost Item: b7accd7d7fd66829c12d9f0748c03063
- Child Cost Item: d52fc59e2cdaccf3906d3c873a86f1e0
- Child Cost Item: f29949adc2acd5eae2cf07ee8c4b566c
- Child Cost Item: 38e7b6e68d8d438bfc87e49e25bf2675
- Child Cost Item: cb2019cf826497839cb920cceb5e2e48
- Child Cost Item: e09317ae2cb6a91980dddf455b394097
- Child Cost Item: fe53aed01a350a1c3dc87e3cf6e369e5